0000000000673543

AUTHOR

R. Bergmann

Knowledge Discovery from Microbiology Data: Many-Sided Analysis of Antibiotic Resistance in Nosocomial Infections

Nosocomial infections and antimicrobial resistance (AR) are highly important problems that impact the morbidity and mortality of hospitalized patients as well as their cost of care. The goal of this paper is to demonstrate our analysis of AR by applying a number of various data mining (DM) techniques to real hospital data. The data for the analysis includes instances of sensitivity of nosocomial infections to antibiotics collected in a hospital over three years 2002-2004. The results of our study show that DM makes it easy for experts to inspect patterns that might otherwise be missed by usual (manual) infection control. However, the clinical relevance and utility of these findings await th…

research product

177Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment

Background: Metastatic bone lesion is a common syndrome of many cancer diseases in an advanced state. The major symptom is severe pain, spinal cord compression, and pathological fracture, associated with an obvious morbidity. Common treatments including systemic application of bisphosphonate drugs aim on pain reduction and on improving the quality of life of the patient. Particularly, patients with multiple metastatic lesions benefit from bone-targeting therapeutic radiopharmaceuticals. Agents utilizing beta-emitting radionuclides in routine clinical praxis are, for example, [89Sr]SrCl2 and [153Sm]Sm-EDTMP. No-carrier-added (n.c.a.) 177Lu is remarkably suitable for an application in this sc…

research product

Additional file 1: of Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid

Figure S1. Quality control of [68Ga]DOTAZOL by means of cross checked radio-HPLC and radio-TLC, as a representative of 68Ga-labelled bisphosphonates. A: After 15 min reaction time. B: After SPE purification. A(HPLC): Rt([68Ga]DOTAZOL) = 0.6 min. (88 %), Rt([68Ga]DFO) = 4.1 min. (12 %). B(HPLC): Rt([68Ga]DOTAZOL) = 0.6 min. (98 %). A(TLC): Rf([68Ga]DOTAZOL) = 0.1 (85 %), Rf([68Ga]acetylacetonate) = 0.9 (15 %). B(TLC): Rf([68Ga]DOTAZOL) = 0.1 (99 %). Control(TLC): Rf([68Ga] acetylacetonate) = 0.9 (99 %). Figure S2. Radio-HPLC of [177Lu]DOTAZOL on a Zorbax 300SB-C18 9,4 × 250 mm 5 μ, A = 100 mM TEAP pH = 2,24, isocratic flow: 1 ml/min. Figure S3. Radio-HPLC of urine and blood samples after adm…

research product